Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells.
Niyonsaba. François F; Ushio. Hiroko H; Hara. Mutsuko M; Yokoi. Hidenori H; Tominaga. Mitsutoshi M; Takamori. Kenji K; Kajiwara. Naoki N; Saito. Hirohisa H; Nagaoka. Isao I; Ogawa. Hideoki H; Okumura. Ko K
Key Findings
- LL‑37 and beta‑defensins boost IL‑31 gene expression and protein release from human mast cells
- IL‑31 production is reduced by inhibitors of G‑protein signaling and PI3K, indicating these pathways are involved
- Activation of MAPK pathways (p38, ERK, JNK) is required for IL‑31 release, and LL‑37 also increases other itch‑related mediators like IL‑2, IL‑4, IL‑6, GM‑CSF, NGF, PGE2, and leukotriene C4
Practical Outcomes
- If you’re thinking about using LL‑37 as a supplement or topical agent, be aware it may provoke itching and skin inflammation, especially in people prone to psoriasis or other skin disorders. Limiting dose or avoiding LL‑37 when you have sensitive skin could reduce unwanted itch side effects.
Summary
The study shows that the antimicrobial peptide LL‑37 (and related beta‑defensins) can make human mast cells release IL‑31, a chemical that causes itching, along with other inflammatory substances. This means LL‑37 isn’t just an antimicrobial; it can also trigger skin irritation and inflammation through specific cell signaling pathways.
Abstract
In addition to their microbiocidal properties, human beta-defensins (hBDs) and cathelicidin LL-37 stimulate a number of mammalian cell activities, including migration, proliferation, and cytokine/chemokine production. Because hBDs and LL-37 cause mast cells to release pruritogens such as histamine and PGs, we hypothesized that these peptides would stimulate the secretion of a novel pruritogenic mediator IL-31, predominantly produced by T cells. hBDs and LL-37 enhanced IL-31 gene expression and IL-31 protein production and release in the human mast cell line LAD2, as well as in peripheral blood-derived cultured mast cells, suggesting that mast cells are another source of IL-31. Moreover, the expression of IL-31 was elevated in psoriatic skin mast cells, and hBD-2-4 and LL-37, but not hBD-1, enhanced its expression in vivo in rat skin mast cells. hBDs and LL-37 also induced the release of other pruritogenic mediators, including IL-2, IL-4, IL-6, GM-CSF, nerve growth factor, PGE(2), and leukotriene C(4), and increased mRNA expression of substance P. hBD- and LL-37-mediated IL-31 production/release was markedly reduced by pertussis toxin and wortmannin, inhibitors of G-protein and PI3K, respectively. As evidenced by the inhibitory effects of MAPK-specific inhibitors, hBD-2-4 and LL-37 activated the phosphorylation of MAPKs p38, ERK, and JNK that were required for IL-31 production and release. The ability of hBDs and LL-37 to stimulate the production and release of IL-31 by human mast cells provides a novel mechanism by which skin-derived antimicrobial peptides/proteins may contribute to inflammatory reactions and suggests a central role of these peptides in the pathogenesis of skin disorders.
Study Information
pubmed
2010
2010-02-26T00:00:00.000Z
10.4049/jimmunol.0900712
277
71